[{"_1":2,"_3":-5,"_4":-5},"loaderData",{"_5":6,"_7":8},"actionData","errors","root",{"_102":103},"en-item",{"_9":10,"_10":11},"kind","item",{"_12":13,"_14":15,"_16":17,"_18":19,"_20":21,"_22":23,"_24":25,"_26":27,"_28":29,"_30":31,"_32":31,"_33":34,"_35":36,"_37":38,"_39":40,"_41":42,"_43":44,"_45":46,"_47":-5,"_48":49,"_50":-5,"_51":-5,"_52":53,"_54":55,"_56":57,"_58":42,"_59":42,"_60":61,"_62":42,"_63":64},"id","soh79pgpfv9nd84zg3onifzzh","revision",2,"title","STERIS plc以21亿美元收购Xodus Medical","originalTitle","STERIS plc (0001757898) (Filer)","summary","STERIS plc宣布将以21亿美元现金收购Xodus Medical, Inc.，并可能获得最高1.5亿美元的业绩对赌支付。交易预计在2026年底完成，需满足监管审批等条件。","reason","STERIS plc宣布以21亿美元现金收购Xodus Medical, Inc.，并可能获得最高1.5亿美元的业绩对赌支付，交易预计在2026年底完成，需满足监管审批等条件。","source",{"_12":93,"_94":95,"_9":96,"_97":42,"_98":99,"_100":101},"links",{"_90":91,"_78":92},"publishedAt","2026-10-13T20:29:56.000Z","discoveredAt","2026-10-13T22:55:53.601Z","timelineAt","category","ai-products","tags",[84,85,86,87,88,89],"stockSymbols",[83],"score",75,"selected",true,"channel","news","story",{"_73":74,"_16":75},"x","readingMode","full","author","language","body",{"_64":77,"_78":-5,"_79":80,"_81":82},"outline",[],"relatedStories",[76],"indexable","markdownAvailable","group",{"_65":66,"_45":67,"_68":69,"_70":71,"_72":71},"hasTranslation","bodyLanguage","zh","factId","fHuqTaKHXLJw",{"_73":74,"_16":75},"reportCount",1,"additionalSourceCount",0,"developmentCount","publicId","84cf52bb-002a-4b00-ac5b-68ea9b4fe222","STERIS收购Xodus Medical",{"_73":74,"_16":75},"

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 11, 2026

STERIS plc

(Exact Name of Registrant as Specified in Charter)

\n\n\n\n\n\n\n\n\n\n\n\n\n\n

Ireland

001-38848

98-1455064

(State or Other Jurisdiction
of Incorporation)

(Commission

File Number)

(IRS Employer
Identification No.)

70 Sir John Rogerson’s Quay

Dublin 2, Ireland D02 R296

(Address of Principal Executive Offices)

+353 1 232 2000

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

\n\n\n

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

\n\n\n

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

\n\n\n

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

\n\n\n

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n	\n	\n	\n
Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Ordinary Shares, $0.001 par value		STE		New York Stock Exchange
2.700% Senior Notes due 2031		STE/31		New York Stock Exchange
3.750% Senior Notes due 2051		STE/51		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

\n\n\n

ITEM 1.01.

Entry into a Material Definitive Agreement.

On October 11, 2026, STERIS Corporation (“Purchaser”), a wholly owned subsidiary of STERIS plc (“STERIS” or the “Company”), entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with Craig E. Kaforey, individually, as trustee of the Craig E. Kaforey Legacy Trust and as seller’s representative, and Mark A. Kaforey, individually and as trustee of the Mark A. Kaforey Legacy Trust (collectively, the “Sellers”), to acquire all of the equity interests of Xodus Medical, Inc., a specialty surgical products business based in Pennsylvania, and certain related affiliates (collectively, “Xodus”). The Purchase Agreement provides that, upon the terms and subject to the conditions set forth therein, Purchaser will acquire Xodus (the “Acquisition”) for $2.1 billion in cash at closing, subject to customary adjustments. The Purchase Agreement also provides for additional potential earnout consideration of up to $150 million based on the achievement of specified post-closing performance targets in calendar 2028. The Acquisition is expected to be financed primarily with debt and is anticipated to close by December 31, 2026, subject to customary closing conditions and regulatory approvals.

购买协议规定了常规的陈述、保证、承诺和协议。购买协议还对卖方施加了常规的保密、不得招揽客户和不竞争义务。购买协议为买方和卖方提供了某些终止权利，包括如果在2027年7月12日或之前未完成收购，买方或卖方均可终止购买协议，根据某些情况，该期限可能会延长至2028年1月11日。收购的完成取决于满足或放弃若干常规条件，包括获得必要的监管批准。

就签订购买协议和收购事宜，STERIS和买方与摩根大通银行，N.A.（“摩根大通”）和高盛银行美国公司（“高盛”和，与摩根大通一起，统称为“承诺方”）于2026年10月11日签订了一份过桥融资承诺，根据该承诺，承诺方承诺向STERIS提供总额高达20亿美元的高级无担保过桥融资（“过桥融资”），具体条件以其中规定为准。过桥融资下的承诺金额可根据从永久融资或收购关闭前或后出售资产中筹集的净收益金额，按照等额方式减少，但需符合常规条件。

前瞻性声明

本8-K形式的当前报告包含有关STERIS或其行业、产品或活动的某些趋势、期望、预测、估计或其他前瞻性信息，这些信息旨在符合1995年《私人证券诉讼改革法案》及其他法律法规规定的“前瞻性声明”的保护。前瞻性声明仅针对声明作出的日期，并可通过使用诸如“可能”、“将”、“预期”、“相信”、“预计”、“计划”、“估计”、“预测”、“目标”、“预测”、“前景”、“影响”、“潜力”、“信心”、“改善”、“乐观”、“实现”、“订单”、“订单积压”、“满意”、“趋势”和“寻求”等前瞻性术语，或这些术语的否定形式或其他变化形式或类似术语来识别。这些前瞻性声明基于管理层对STERIS业务、其所在行业以及管理层当前信念和假设的当前预期、估计或预测，并受不确定性和情况变化的影响。

本表格8-K的读者应理解，这些声明并非对业绩或结果的保证。许多因素可能导致实际结果与前瞻性声明中的内容有重大差异，包括但不限于本表格8-K中所述内容。无法保证STERIS证券文件中所述事项或与任何监管行动、行政程序、政府调查、诉讼、警告信、成本削减、业务策略、收益或收入趋势或未来财务结果相关的任何结果或结果时间的保证。可能导致实际结果与前瞻性声明中的内容有重大差异的其他潜在风险和不确定性包括但不限于：(a) 任何立法、法规或命令（包括但不限于任何新的贸易、法规或命令）对STERIS及其运营的影响，这些可能由美国政府或国会实施，或由非美国政府对此作出的反应，(b) 运营成本、价格压力（包括但不限于由于通货膨胀导致的）以及客户流失和业务中断。

\n（包括但不限于与员工、客户、供应商的关系维护困难）比预期更大，导致利润率下降，（c）国际动荡、军事冲突、经济衰退、汇率波动和网络安全事件以及对STERIS预期增长、业绩或其他结果的任何影响，（d）医疗政策或政府或其他第三方付款人报销水平的变化，（e）遵守法律、法院裁决、认证、法规或其他监管行动的可能性，或任何待决或威胁诉讼的结果，可能会延迟、限制或阻止新产品或服务的推出，影响现有产品或服务的生产、供应和/或营销，导致未覆盖的成本，或以其他方式影响STERIS的业绩、结果、前景或价值，（f）STERIS运营所在司法管辖区税法或解释的变化或某些所得税条约的采用，这可能会增加其合并税负，包括导致STERIS被视作美国居民以进行美国联邦税目的税法变化，或由于STERIS公司结构而产生的关税和/或其他贸易壁垒的影响，（g）STERIS行业内整合和竞争加剧的影响，这可能会对其定价策略、制造策略施加压力或导致其产品和服务需求下降，（h）与劳动力相关的问题对STERIS运营的影响，例如罢工、工会谈判失败和其他劳动力中断，或其无法招聘或留住管理人员和其他人员，（i）STERIS的债务水平限制财务灵活性或增加未来的借贷成本，（j）信用可用性和定价的变化，以及STERIS及其客户和供应商在需要时能否以有利条件或甚至完全获得信用市场的影响，（k）预期的财务结果、预期收入、生产率改进、成本节约、增长协同效应和其他收购、重组和剥离的预期收益可能无法实现或比预期少，这可能是由于未知或不可估量的负债、减值或预期整合成本的增加，或与收购业务整合相关的困难，（l）关于北卡罗来纳州新卓越中心及其相关设施整合计划的预期效益、费用和现金支出可能不准确或无法在预期时间内实现，甚至无法实现，（m）完成收购所需的监管批准可能无法获得，可能比预期时间更长，可能施加不利条件，以及STERIS可能无法在预期时间内完成收购，甚至无法完成，（n）从收购中预期的成本节约、税务利益和其他协同效应可能无法实现，或实现时间可能比预期更长，包括收购可能不会产生预期的现金税务利益或在预期时间内或程度上产生，以及（o）在STERIS最新年度报告（表格< span>10-K）和其他向证券交易委员会提交的报告中描述的其他风险。

读者被警告不要过度依赖本表格8-K中包含的任何前瞻性声明，该声明仅反映本文件日期的情况。STERIS没有义务根据新信息、未来发展或其他情况更新或修订任何前瞻性声明，除非适用法律要求。

签名

根据1934年《证券交易法》的要求，注册人已 duly 促使本报告由此处授权的代表签署。

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n

\n\n	\n
STERIS plc
\n
由		/s/ J. Adam Zangerle
\n		J. Adam Zangerle
\n		高级副总裁、总法律顾问兼公司秘书

日期：2026年10月13日

","original","zhKind","translation","complete",false,"STE","公司与财报","并购","行业与主题","政策与监管","宏观与美联储","观点与解读","aihot","/items/soh79pgpfv9nd84zg3onifzzh","https://www.sec.gov/Archives/edgar/data/1757898/000119312526420487/0001193125-26-420487-index.htm","rss-sec-xbrl","name","SEC · EDGAR 财务披露","rss","firstParty","iconUrl","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar&exp=1792195200&sig=4eab1165515e57e2","iconSrcSet","/api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-48&exp=1792195200&sig=df95c58c297800b1 48w, /api/img-proxy?u=https%3A%2F%2Fwww.sec.gov%2Fthemes%2Fcustom%2Fuswds_sec%2Fassets%2Fimg%2Ffavicons%2Fapple-touch-icon.png&mode=avatar-96&exp=1792195200&sig=2a4278e6e5e85947 96w","changelogVersion","2026-10-01T08:00"]